Physician profile

John P Tuttle

Urology · Lexington, KY

NPI 1396728358

$1,876.33

in general payments reported to CMS, 2019-2025

22 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astellas Pharma US INC $932.66 2019-2022
Antares Pharma, INC. $224.84 2019-2022
Duchesnay USA Incorporated $132.71 2019
Coloplast Corp $60.35 2019-2021
Bayer Healthcare Pharmaceuticals INC. $57.11 2021-2022
Janssen Biotech, INC. $54.30 2021-2022
Pfizer INC. $53.72 2019-2020
Endo Pharmaceuticals INC. $50.02 2021-2022
Urovant Sciences INC $48.17 2022
Ferring Pharmaceuticals INC. $43.57 2019
Myovant Sciences INC. $38.72 2021
Allergan, INC. $27.42 2021
C. R. Bard, INC. & Subsidiaries $22.95 2021
Neotract INC. $18.05 2019
Accord Healthcare, INC. $17.55 2022
Show all 22 companies
CompanyGeneral paymentsYearsTop products
Laborie Medical Technologies Corp. $17.05 2021
Clarus Therapeutics INC. $15.00 2021
Karl Storz Endoscopy-America $13.78 2019
Boston Scientific Corporation $12.70 2022
Medtronic USA, INC. $12.66 2020
Amag Pharmaceuticals, INC. $11.91 2019
Abbvie INC. $11.09 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

John P Tuttle

$1,876.33

in general payments reported 2019-2025

Years
2019-2022
Top company
Astellas Pharma US INC

https://glasscript.com/doctor/1000972/john-p-tuttle

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.